Breast Cancer Clinical Trial
Official title:
A Phase I-II Study of Lapatinib and Docetaxel as Neoadjuvant Treatment for HER-2 Positive Locally Advanced/Inflammatory or Large Operable Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, fluorouracil, epirubicin, and
cyclophosphamide, work in different ways to stop the growth of tumor cells, either by
killing the cells or by stopping them from dividing. Lapatinib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as
trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells
to grow and spread. Others find tumor cells and help kill them or carry tumor-killing
substances to them. Giving these treatments before surgery may make the tumor smaller and
reduce the amount of normal tissue that needs to be removed. Giving trastuzumab after
surgery may kill any tumor cells that remain after surgery.
PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of
docetaxel and lapatinib when given with or without combination chemotherapy and to see how
well they work in treating women with locally advanced, inflammatory, or resectable breast
cancer.
OBJECTIVES:
Primary
- Determine the maximum tolerated dose of neoadjuvant therapy comprising docetaxel and
lapatinib ditosylate before or after fluorouracil, epirubicin hydrochloride, and
cyclophosphamide (FEC chemotherapy) in patients with HER2-positive locally advanced,
inflammatory, or large resectable breast cancer. (Phase I)
- Determine the safety of this regimen in these patients. (Phase I)
- Determine the pathological complete response rate in patients treated with neoadjuvant
docetaxel and lapatinib ditosylate followed by FEC chemotherapy, and with neoadjuvant
docetaxel and trastuzumab (Herceptin®) followed by FEC chemotherapy. (Phase II)
Secondary
- Determine the biological activity (i.e., changes in apoptosis and proliferation markers
[PTEN mutation and function, pAkt, mTOR, and associated proteins]) of neoadjuvant
docetaxel and lapatinib ditosylate in these patients. (Phase I)
- Determine adverse events or biological modifications. (Phase I)
- Determine the tolerability of these regimens in these patients. (Phase II)
- Determine the clinical activity of these regimens. (Phase II)
- Identify genes that may predict response in patients treated with docetaxel and
lapatinib ditosylate. (Phase II)
OUTLINE: This is a multicenter, open-label, phase I dose-escalation study of docetaxel and
lapatinib ditosylate followed by a randomized phase II study. Patients enrolled in the phase
II portion of the study are stratified by institution and disease status (locally advanced
disease vs large operable tumor).
- Phase I (completed as of 5/26/2010): Patients receive docetaxel IV over 1 hour on day 1
and oral lapatinib ditosylate once daily on days 1-21. Treatment repeats every 3 weeks
for 4 courses. Two additional courses may be given at the discretion of the physician.
- Cohorts of 3-6 patients receive escalating doses of docetaxel and lapatinib
ditosylate until the maximum tolerated dose (MTD) is determined. The MTD is
defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients
experience dose-limiting toxicity (DLT).
- Phase I bridge step (completed as of 5/26/2010): Patients receive FEC chemotherapy
comprising fluorouracil IV over 15 minutes, epirubicin hydrochloride IV over 60
minutes, and cyclophosphamide IV over 60 minutes on day 1. Treatment repeats every 3
weeks for 3 courses. Patients also receive docetaxel and lapatinib ditosylate as in
phase I at the MTD for up to 3 courses.
- Cohorts of 3-6 patients receive de-escalating doses of docetaxel and lapatinib
ditosylate in combination with FEC chemotherapy until the MTD is determined. The
MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients
experience DLT.
- Phase II: Patients are randomized to 1 of 3 treatment arms.
- Arm I: Patients receive docetaxel and lapatinib ditosylate at the MTD as in the
bridge step of phase I followed by FEC chemotherapy.
- Arm II: Patients receive docetaxel IV over 60 minutes and trastuzumab (Herceptin®)
IV over 30-90 minutes on days 1, 8, and 15. Patients then receive FEC chemotherapy
as in the bridge step of phase I. Treatment with docetaxel and trastuzumab repeats
every 3 weeks for 3 courses in the absence of disease progression or unacceptable
toxicity.
- Arm III: Patients receive docetaxel IV over 60 minutes, lapatinib ditosylate at
the MTD as in the bridge step of phase I, and trastuzumab (Herceptin®) IV over
30-90 minutes on days 1, 8, and 15. Patients then receive FEC chemotherapy as in
the bridge step of phase I. Treatment with docetaxel, lapatinib ditosylate, and
trastuzumab repeats every 3 weeks for 3 courses in the absence of disease
progression or unacceptable toxicity.
All patients then undergo surgery to remove the tumor. Patients may then receive trastuzumab
every 3 weeks for 1 year.
Blood samples are collected at baseline and periodically during study for pharmacokinetic
studies. Patients also undergo tumor biopsies at baseline and periodically during study for
laboratory studies. Blood and tissue samples are analyzed by quantitative reverse
transcriptase polymerase chain reaction for biomarker profiling (HER1-3, Akt 1-3, mTOR,
RICTOR, RAPTOR, CCND1, p21, survivin, PTEN), immunohistochemistry, fluorescent in situ
hybridization (TopoII, HER2), and proteomics.
After completion of study treatment, patients are followed periodically.
PROJECTED ACCRUAL: A total of 150 patients will be accrued for the phase II.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |